Buscar
Congreso SOLACI

Artículos del autor

Dr. Andrés Rodríguez

Member of the Editorial Board of solaci.org
Aorta

Transcatheter Pulmonary Valve Implantation with a Self-Expanding Valve: Outcomes at 3 Years

Pulmonary regurgitation (PR) is a common condition in patients who have undergone surgical repair of Tetralogy of...
Dr. Andrés Rodríguez -
Antiplatelet

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a...
Dr. Andrés Rodríguez -
Bifurcations

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary...
Dr. Andrés Rodríguez -
Femoropopliteal

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery...
Dr. Andrés Rodríguez -
Chronic Coronary Syndromes

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization....
Dr. Andrés Rodríguez -
Coronary disease

FRANCE TAVI Registry: Coronary Adverse Events After TAVI

Between 30% and 70% of patients undergoing transcatheter aortic valve implantation (TAVI) have coronary artery disease (CAD)....
Dr. Andrés Rodríguez -
Coronary disease

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well...
Dr. Andrés Rodríguez -
Chronic Ischemic cardiopathy

Early and Late Outcomes with the ABSORB Bioresorbable Scaffold

Coronary angioplasty with drug-eluting stents (DES) is associated with a 2-3% annual incidence of stent-related events, a...
Dr. Andrés Rodríguez -

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

Dr. Omar Tupayachi - 0
In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Dr. Omar Tupayachi - 0
Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Dr. Omar Tupayachi - 0
Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...

Noticias Institucionales

How to apply for the SOLACI Research 2025 Grant? Step-by-step explanation video

solaci - 0
You can now rewatch the virtual event we held on April 9th, where we thoroughly reviewed the steps to apply for the SOLACI Research...

April 9 – How to Apply for the SOLACI Research Grant 2025? Virtual Zoom Event

solaci - 0
The Latin American Society of Interventional Cardiology invites you to a new virtual event hosted by the SOLACI Research Department, aimed at clarifying doubts,...

Watch our event on Evidence and Controversies of Renal Denervation in 2025

solaci - 0
You can now watch our event, held in collaboration with Medtronic, titled "Evidence and Controversies of Renal Denervation in 2025." The event featured international experts...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad